2016 global life sciences sector outlook

Deloitte’s yearly look at the topics, trends, issues, and challenges impacting the global life sciences sector.

Global health care spending

Expected drivers of growth

Economic uncertainty — Eurozone crisis
Currency devaluation
Sanctions and falling oil prices
Recession
Stagnating economies

Expected constraints to growth

Regulatory agencies continue to exert pressure on life sciences
Increased focus on R&D
Increased focus on clinical trials

© 2015. For information, contact Deloitte Touche Tohmatsu Limited.

To learn more about the trends, challenges, and issues impacting the global life sciences sector, please visit www.deloitte.com/lifesciencesoutlook

Current market size

Global P&L

North America

Latin America

Europe

Asia Pacific

Med tech

$13 billion

Digital health

Healthcare

Wearables

Social media

Healthcare

Digital

Apps

Managed services

Healthcare

Clinical development

Electronic medical records

Drug identification

Telehealth, mHealth

Population

Aging

Growing prevalence of chronic diseases
Rising consumer awareness

Global

GDP

% of GDP spent on health care globally is expected to decrease to 9.1% by 2019

Economic uncertainty — Eurozone crisis
Currency devaluation
Sanctions and falling oil prices

Rising consumer awareness
Growing prevalence of chronic diseases
Rising population

Key trends impacting the sector

Supply drivers

Demographics
Rising population
Population aging
Growing prevalence of chronic diseases

Economic uncertainty — Eurozone crisis
Currency devaluation
Sanctions and falling oil prices

Demand drivers

Digital
Technology

Healthcare

Mobile devices

Global

Evolving models

Telehealth, mHealth
Wearables
Social media

Digital

Apps

Managed services

Healthcare

Clinical development

Electronic medical records

Drug identification

Telehealth, mHealth

Economic uncertainty — Eurozone crisis
Currency devaluation
Sanctions and falling oil prices

Global

Health reforms

US Affordable Care Act
Reform-driven drug pricing

Global

Health reforms

US Affordable Care Act
Reform-driven drug pricing

Regulatory implications of technology-enabled care

Regulatory agencies continue to exert pressure on life sciences
Increased focus on R&D
Increased focus on clinical trials

Regulatory agencies continue to exert pressure on life sciences
Increased focus on R&D
Increased focus on clinical trials

Regulatory implications of technology-enabled care

Regulatory agencies continue to exert pressure on life sciences
Increased focus on R&D
Increased focus on clinical trials

Regulatory implications of technology-enabled care

Regulatory agencies continue to exert pressure on life sciences
Increased focus on R&D
Increased focus on clinical trials

Regulatory implications of technology-enabled care

Regulatory agencies continue to exert pressure on life sciences
Increased focus on R&D
Increased focus on clinical trials

Regulatory implications of technology-enabled care

Regulatory agencies continue to exert pressure on life sciences
Increased focus on R&D
Increased focus on clinical trials

Regulatory implications of technology-enabled care

Regulatory agencies continue to exert pressure on life sciences
Increased focus on R&D
Increased focus on clinical trials